Takeda enrolls first patient in Ixazomib PhIII trial; Anpac early cancer detection breakthrough?;

> Takeda says it has enrolled its first patient in a global Phase III study of Ixazomib as maintenance therapy for newly diagnosed multiple myeloma. Release

> Israel-based Pluristem Therapeutics ($PSTI) said Japan's Pharmaceuticals and Medical Devices Agency agreed with the proposed quality and large-scale manufacturing methods for PLX-PAD cells for use in clinical trials. Release

> Sino Biopharmaceutical's first quarter highlights its entry into hospital business through the acquisition of Chia Tai Shaoyang Orthopedic Hospital in Hunan Province. Release (PDF)

> Anpac Bio-Medical Science CEO Chris Yu presented what event organizers said was "breakthrough" early cancer detection technology research results at the "2015 Nobel Prize Laureate Summit on Biomedical Science: Frontiers in Cancer Research" in Tianjin, China. Release

> Australia-listed Sun Biomedical has agreed to buy Dimerix Bioscience, a public unlisted clinical stage drug discovery and development company based in Melbourne. Report

> WuXi PharmaTech ($WX) is planning a May 14 call in the U.S., with management's move to take company private highlighted in release that accompanied May 13 first quarter earnings. Release

> HK-listed Luye Pharma has completed three clinical studies of 172 patients in the U.S. for an investigational drug product of risperidone (LY03004) for the treatment of schizophrenia and plans to approach the FDA to discuss a possible NDA. Release (PDF)